Y‑Trap creates multispecific antibodies that remodel the tumor immune microenvironment by simultaneously targeting multiple immune checkpoints and co‑stimulatory receptors. Their engineered bispecific and trispecific formats convert immunosuppressive phenotypes into pro‑inflammatory states, enhancing T‑cell activation and enabling synergistic combination with existing cancer therapies. The platform serves pharma, biotech, and research organizations developing next‑generation immuno‑oncology treatments.
Funding
$27.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many solid tumors create an immunosuppressive microenvironment that blocks effective anti‑tumor immune responses, allowing cancer cells to evade detection and resist existing immunotherapies such as single‑target checkpoint inhibitors.
Solution
Y‑Trap engineers novel multispecific antibodies that go beyond traditional checkpoint blockade to actively remodel the tumor immune microenvironment. By simultaneously engaging multiple immune regulators, these antibodies convert suppressive phenotypes into a pro‑inflammatory state, enhancing T‑cell activation and infiltration. The platform leverages antibody engineering and bispecific/trispecific formats to target distinct pathways that cooperate in immune evasion. Preclinical data demonstrate restored immune surveillance and synergistic activity with existing therapies. Y‑Trap’s approach aims to provide a next‑generation immuno‑oncology modality that can be combined with standard of care to improve response rates across a broad range of cancers.
Target Audience
Primary customers are pharmaceutical and biotech companies developing immuno‑oncology therapeutics, as well as academic and contract research organizations focused on tumor immunology and antibody engineering.
Features
- Multispecific antibody formats (bispecific, trispecific) that bind and modulate several immune checkpoints or co‑stimulatory receptors in a single molecule
- Engineered Fc regions optimized for tumor‑localized activity and reduced systemic toxicity
- Platform for rapid generation and screening of antibody combinations tailored to specific tumor microenvironment signatures
- Integrated preclinical validation pipeline including functional immune assays and in vivo tumor models
- Designed for compatibility with combination regimens such as chemotherapy, radiation, or existing checkpoint inhibitors